Trial Profile

A Phase I clinical trial evaluating TLX101 in Chinese patients with newly diagnosed glioblastoma (GBM)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Apr 2023 New trial record
11 Apr 2023 According to a Telix Pharmaceuticals media release, this study establishing the safety profile of TLX101 in a Chinese patient population, which enabling Chinese patients to be enrolled in planned global pivotal registration trial of TLX101
11 Apr 2023 According to a Telix Pharmaceuticals media release, investigational new drug (IND) application was submitted by Telix partner in the Greater China region, Grand Pharmaceutical Group Limited (Grand Pharma).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com